Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ams; our planned Phase 2 clinical studies and the ability of those studies to successfully evaluate HspE7 as a potential treatment for CIN 1 and CIN 2/3; the structure and location of our planned Phase 2 trials; completion of the second protocol for CIN 1; potential uses for Poly-ICR; our ability to advance Poly-ICR resulting in revenue generation and internal development; the ability of Poly-ICR to provide us with near-term revenue opportunity; the development of Poly-ICR for treatment of GW and actinic keratosis; completion of development activities and the filing of an IND application in connection with Poly-ICR; finalizing manufacturing and formulation protocols and filing an IND in connection with Hsp 6/11; execution of our corporate restructuring as planned; our ability to retain key personnel; and our plan to expand corporate development efforts and the potential results of such efforts.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that our planned corporate restructuring will not have the anticipated affect; that we will not succeed in forming strategic alliances and, if we do, the possibility that such alliances will not allow us to realize the greatest value for our programs; that we will not commence Phase 2 clinical studies as planned and, if we do, that such studies will not support the use of HspE7 as a treatment for CIN 1 or CIN 2/3; that we will not complete the second protocol for the CIN 1 indication; that Poly-IRC will not be useful as a broad immune stimulatory agent or vaccine adjuvant; that we will not be able to advance Poly-ICR to generate revenue or for internal development; that Poly-ICR will not provide us with near-term reve
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The report on the Global Smart Sensor Market ... for revenue forecasts and market trends. It expects the ... 2013 to 2018. At the projected rate, the market ... by 2018. , Browse through the Global Smart Sensor ... the market segmentation and in-depth analysis supported by a ...
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... November 25, 2014 Whitehouse Laboratories ... joined the Morris County (New Jersey) Chamber of ... a leading business organization in the North Jersey ... further engage some key clients in the pharmaceutical ... the geographic area. Membership enables Whitehouse Laboratories a ...
(Date:11/26/2014)... 2014 Global biostimulants market is ... at an estimated CAGR of 12.5%. In order ... products with least ecological impacts, farmers are looking ... boost crop yield more effectively & efficiently. Biostimulants ... improve the return on investments. , Leading companies ...
Breaking Biology Technology:Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4
... FRANCISCO, July 8 Nile Therapeutics, Inc. (Nasdaq: ... therapeutics for heart failure patients, today announced that it has ... securities of the Company for aggregate gross proceeds of approximately ... acted as the exclusive placement agent for the transaction. , ...
... CAMBRIDGE, England, July 8 Funxional Therapeutics ... first Phase,I study with FX125L, an orally available small ... Spectrum Chemokine Inhibitors (BSCIs). , ... in the United,States. FX125L was well tolerated at all ...
... CHENGDU, China, July 8 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... and supplier of,modernized traditional Chinese medicine ("TCM") based in Chengdu, ... its common stock shareholders.,The dividend of $0.025 will be paid ... actual distribution occurring on or about September 10, 2009. , ...
Cached Biology Technology:Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 2Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 3Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 4Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action 2Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders 2
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2
... identified a gene that drives the development of tumours in ... the first time that the gene CUX1 has been broadly ... CUX1 is deactivated, a biological pathway is activated that increases ... being used in the clinic and are in development thus ...
... According to Gertrude Stein, "A rose is a rose ... be the case when it comes to the rose,s scent. ... that as much as 30 percent of the large array ... substantial variation is in turn reflected by variability in how ...
... eye following even a mild traumatic brain injury. While the ... Nature suggest that the brain,s protective coverings may ... newly developed mouse trauma model, senior author Dorian McGavern, Ph.D., ... (NINDS), part of the National Institutes of Health, watched specific ...
Cached Biology News:Gene promotes 1 in 100 of tumors 2Extensive variability in olfactory receptors influences human odor perception 2Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3
... T antigen initiates replication from ... in the presence of the ... can be used in conjunction ... Kit cat. no. 8050. ...
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
Request Info...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
Biology Products: